Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $87.06 | 5 | 100.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $34.22 | 1 | $0 (2024) |
| Biofrontera Inc. | $26.56 | 3 | $0 (2024) |
| LEO Pharma Inc. | $26.28 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $87.06 | 5 | E.R. Squibb & Sons, L.L.C. ($34.22) |
All Payment Transactions
5 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/15/2024 | LEO Pharma Inc. | ADBRY (Biological) | Food and Beverage | In-kind items and services | $26.28 | General |
| Category: DERMATOLOGY | ||||||
| 08/20/2024 | Biofrontera Inc. | AMELUZ (Drug), BF-RhodoLED, XEPI | Food and Beverage | Cash or cash equivalent | $20.66 | General |
| Category: DERMATOLOGY | ||||||
| 08/20/2024 | Biofrontera Inc. | AMELUZ (Drug), BF-RhodoLED, XEPI | Food and Beverage | Cash or cash equivalent | $4.25 | General |
| Category: DERMATOLOGY | ||||||
| 08/20/2024 | Biofrontera Inc. | AMELUZ (Drug), BF-RhodoLED, XEPI | Food and Beverage | Cash or cash equivalent | $1.65 | General |
| Category: DERMATOLOGY | ||||||
| 06/20/2024 | E.R. Squibb & Sons, L.L.C. | Sotyktu (Drug) | Food and Beverage | Cash or cash equivalent | $34.22 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 919 | 1,466 | $376,473 | $97,769 |
| 2022 | 13 | 823 | 1,135 | $333,666 | $83,904 |
| 2021 | 15 | 879 | 1,134 | $326,650 | $90,113 |
| 2020 | 10 | 484 | 662 | $171,135 | $44,311 |
All Medicare Procedures & Services
51 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 167 | 220 | $80,080 | $23,134 | 28.9% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 110 | 144 | $73,329 | $16,103 | 22.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 145 | 204 | $50,388 | $15,605 | 31.0% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 91 | 105 | $39,060 | $9,484 | 24.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 72 | 72 | $26,280 | $6,939 | 26.4% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 97 | 125 | $30,750 | $6,541 | 21.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 30 | 34 | $16,626 | $5,818 | 35.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 37 | 37 | $20,498 | $4,943 | 24.1% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 75 | 419 | $13,408 | $2,966 | 22.1% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2023 | 24 | 35 | $8,680 | $1,834 | 21.1% |
| 11104 | Punch biopsy, first skin growth | Office | 2023 | 12 | 12 | $5,388 | $1,585 | 29.4% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2023 | 29 | 29 | $7,366 | $1,466 | 19.9% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 30 | 30 | $4,620 | $1,350 | 29.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 152 | 188 | $66,364 | $19,330 | 29.1% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 121 | 163 | $78,892 | $16,619 | 21.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 127 | 167 | $40,080 | $11,994 | 29.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 96 | 96 | $33,984 | $7,396 | 21.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 36 | 48 | $22,800 | $7,096 | 31.1% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 70 | 79 | $27,887 | $6,564 | 23.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 32 | 32 | $17,216 | $4,230 | 24.6% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 65 | 80 | $19,160 | $3,936 | 20.5% |
| 11104 | Punch biopsy, first skin growth | Office | 2022 | 13 | 14 | $5,964 | $1,833 | 30.7% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2022 | 27 | 27 | $6,669 | $1,491 | 22.4% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 44 | 196 | $6,076 | $1,392 | 22.9% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2022 | 17 | 22 | $5,170 | $1,134 | 21.9% |
About Silke Heinisch, MD, PHD
Silke Heinisch, MD, PHD is a Pediatric Dermatology healthcare provider based in Soquel, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/09/2010. The National Provider Identifier (NPI) number assigned to this provider is 1649590910.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Silke Heinisch, MD, PHD has received a total of $87.06 in payments from pharmaceutical and medical device companies, with $87.06 received in 2024. These payments were reported across 5 transactions from 3 companies. The most common payment nature is "Food and Beverage" ($87.06).
As a Medicare-enrolled provider, Heinisch has provided services to 3,105 Medicare beneficiaries, totaling 4,397 services with total Medicare billing of $316,095. Data is available for 4 years (2020–2023), covering 51 distinct procedure/service records.
Practice Information
- Specialty Pediatric Dermatology
- Other Specialties Student in an Organized Health Care Education/Training Program, Dermatology
- Location Soquel, CA
- Active Since 06/09/2010
- Last Updated 12/03/2024
- Taxonomy Code 207NP0225X
- Entity Type Individual
- NPI Number 1649590910
Products in Payments
- Sotyktu (Drug) $34.22
- AMELUZ (Drug) $26.56
- ADBRY (Biological) $26.28
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.